No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Pfizer Inc. closed 16.17% below its 52-week high of $31.54, which the company achieved on July 30th.

However, Pfizer's revenue guidance for 2025 doesn't look particularly exciting. The company expects its top line to come in ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

The Schwab U.S. Dividend Equity ETF offers automatic diversification, income, and growth. Read what makes SCHD a solid ...

West Virginia Attorney General (AG) Patrick Morrisey announced a total $17 million settlement agreement with pharmaceutical companies, Pfizer and Ranbaxy after more than a decade of litigation ...

The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...